| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
204,200,000 as of 12/25 |
| Market
Cap: |
104.14(M) |
| Last
Volume: |
190,491 |
Avg
Vol: |
1,523,774 |
| 52
Week Range: |
$0.43 - $1.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
Company Profile CEL-SCI researches and develops drugs and vaccines. Co.'s product, Multikine?, is being developed for the treatment of cancer. Co. has conducted clinical trials on Multikine? in over 200 patients; mostly ones with head and neck cancer, but some studies were conducted in prostate cancer patients, HIV-infected patients and patients with both HIV and HPV-induced cervical dysplasia (the precursor to cervical cancer) in the U.S., Canada, Europe and Israel. Co. owns a pre-clinical technology called L.E.A.P.S?. (Ligand Epitope Antigen Presentation System) used to develop Co.'s CEL-1000, which is being tested for avian flu, herpes simplex, malaria, viral encephalitis, smallpox, vaccinia treatment.
|
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
7,400 |
| Total Buy Value |
$0 |
$0 |
$0 |
$4,514 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
53,333 |
153,333 |
253,333 |
| Total Sell Value |
$0 |
$37,365 |
$171,865 |
$230,345 |
| Total People Sold |
0 |
1 |
2 |
3 |
| Total Sell Transactions |
0 |
1 |
2 |
3 |
| End Date |
2010-04-25 |
2010-01-22 |
2009-07-24 |
2008-07-24 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
Talor Eyal |
CSO |
|
2010-06-30 |
4 |
A |
$0.48 |
$2,400 |
D/D |
5,000 |
444,553 |
|
- |
|
Zimmerman Daniel H |
Senior Vice President |
|
2010-06-30 |
4 |
A |
$0.48 |
$2,760 |
D/D |
5,751 |
330,209 |
|
- |
|
Prichep Patricia B |
Senior Vice President |
|
2010-06-30 |
4 |
A |
$0.48 |
$2,914 |
D/D |
6,071 |
822,300 |
|
- |
|
Kersten Geert R |
CEO |
|
2010-06-30 |
4 |
A |
$0.48 |
$3,675 |
D/D |
7,656 |
3,370,170 |
|
- |
|
Kersten Geert R |
Chief Executive |
|
2010-03-31 |
4 |
A |
$0.64 |
$3,675 |
D/D |
5,742 |
3,362,514 |
|
- |
|
Talor Eyal |
Chief Scientific Officer |
|
2010-03-31 |
4 |
A |
$0.64 |
$2,400 |
D/D |
3,750 |
439,553 |
|
- |
|
Zimmerman Daniel H |
Senior Vice President |
|
2010-03-31 |
4 |
A |
$0.64 |
$2,760 |
D/D |
4,313 |
324,458 |
|
- |
|
Prichep Patricia B |
Senior Vice President |
|
2010-03-31 |
4 |
A |
$0.64 |
$2,914 |
D/D |
4,553 |
816,229 |
|
- |
|
Kinsolving C Richard |
Director |
|
2010-03-18 |
4 |
OE |
$0.22 |
$11,733 |
D/D |
53,333 |
355,580 |
|
- |
|
Kinsolving C Richard |
Director |
|
2010-03-18 |
4 |
S |
$0.70 |
$37,365 |
D/D |
(53,333) |
302,247 |
|
26% |
|
Talor Eyal |
Chief Scientific Officer |
|
2009-12-31 |
4 |
A |
$0.90 |
$8,422 |
D/D |
9,358 |
435,803 |
|
- |
|
Prichep Patricia B |
Senior Vice President |
|
2009-12-31 |
4 |
A |
$0.90 |
$3,046 |
D/D |
3,384 |
811,676 |
|
- |
|
Zimmerman Daniel H |
Senior Vice President |
|
2009-12-31 |
4 |
A |
$0.90 |
$950 |
D/D |
1,055 |
320,145 |
|
- |
|
Zimmerman Daniel H |
Senior Vice PresidentOfficer |
|
2009-12-01 |
3 |
|
$0.00 |
$0 |
D/D |
0 |
319,090 |
|
- |
|
De Clara Maximilian |
President |
|
2009-11-18 |
4 |
S |
$1.35 |
$134,500 |
D/D |
(100,000) |
351,234 |
|
49% |
|
Kersten Geert R |
Chief Executive |
|
2009-09-30 |
4 |
A |
$1.71 |
$14,699 |
D/D |
8,596 |
3,356,772 |
|
- |
|
Prichep Patricia B |
Senior Vice President |
|
2009-09-30 |
4 |
A |
$1.71 |
$10,602 |
D/D |
6,200 |
808,292 |
|
- |
|
Talor Eyal |
Senior Vice President |
|
2009-09-30 |
4 |
A |
$1.71 |
$5,026 |
D/D |
2,939 |
426,445 |
|
- |
|
Young Peter R |
Director |
|
2009-07-06 |
4 |
A |
$0.38 |
$5,000 |
D/D |
13,157 |
247,758 |
|
- |
|
Kinsolving C Richard |
Director |
|
2009-07-06 |
4 |
A |
$0.38 |
$5,000 |
D/D |
13,157 |
302,247 |
|
- |
|
Kersten Geert R |
Chief Executive |
|
2009-07-06 |
4 |
A |
$0.38 |
$5,000 |
D/D |
13,157 |
3,348,176 |
|
- |
|
De Clara Maximilian |
President |
|
2009-07-06 |
4 |
A |
$0.38 |
$5,000 |
D/D |
13,157 |
451,234 |
|
- |
|
Talor Eyal |
Senior Vice President |
|
2009-06-05 |
4 |
S |
$0.58 |
$58,480 |
D/D |
(100,000) |
423,506 |
|
-128% |
|
Talor Eyal |
Senior Vice President |
|
2009-04-03 |
4 |
A |
$0.23 |
$200 |
D/D |
869 |
523,506 |
|
- |
|
Talor Eyal |
Senior Vice President |
|
2008-12-31 |
4 |
A |
$0.28 |
$400 |
D/D |
1,428 |
522,637 |
|
- |
|
300 Records found
|
|
Page 1 of 12 |
|
|